Fort Myers-based cancer lab NeoGenomics is getting a new CEO. Tony Zook, an independent board member, will assume the role.

Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 ...

NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...

The Fort Myers, Fla., oncology testing services company on Friday said Tony Zook, an independent board member since 2023, will succeed Smith as CEO on that date. NeoGenomics said Smith ...

At that time, Tony Zook, an independent board member, will assume the role of CEO. He's been on the board since 2023. Shares fell by more than 17% on the news of a leadership change. To ensure ...

Tony Zook, who has been on the NeoGenomics board since mid-2023, brings leadership experience, including a stint as a public company CEO that concluded with a company sale. However, his experience ...

On Friday, Raymond (NS:RYMD) James maintained a Market Perform rating on NeoGenomics (NASDAQ: NASDAQ:NEO), following the announcement of CEO Chris Smith's retirement and the appointment of Tony Zook ...

In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on NeoGenomics (NEO – Research Report), with a price target of ...

Shares of NeoGenomics tumbled after the oncology testing-services company said its chief executive, Chris Smith, will retire April 1. The stock fell 20%, to $14.91, in afternoon trading Friday. Shares ...